[1] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67:328-357. [2] Kanuri G,Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci,2013,14:11963-11980. [3] Chavez-Tapia NC,Rosso N,Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem,2011,18:1079-1084. [4] 刘晓,朱月永,任杰,等. 医用脂肪乳诱导的肝脂肪变性细胞模型的建立. 肝脏,2010,15:446-448. [5] Yilmaz Y. Review article:fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2012,35:1135-1144. [6] 张程亮,贺雯茜,徐艳娇,等. 果糖诱导非酒精性脂肪性肝病小鼠动物模型的构建和评价. 肝脏,2017,22:700-704. [7] Varela NM,Quinones LA,Orellana M,et al. Study of cytochrome P450 2E1 and its allele variants in liver injury of nondiabetic,nonalcoholic steatohepatitis obese women. Biol Res,2008,41:81-92. [8] 董丽红,张瑞芬,黄菲,等. 油酸诱导单纯性肝脂肪变性细胞模型的建立及应用. 中国药理学通报,2017,22:1622-1626. [9] 晏贤春,胡彬,王赫,等. 游离脂肪酸诱导小鼠肝实质细胞体外脂肪化并加速细胞凋亡. 肝脏,2013,18:306-309. [10] 周红宇,阳学风. 瘦素对L-02肝细胞甘油三酯沉积及乙酰辅酶A羧化酶表达的影响. 实用药物与临床,2011,14:373-375. [11] Iwasaki Y,Kambayashi M,Asai M,et al. High glucose alone,as well as in combination with proinflammatory cytokines,stimulates nuclear factor kappa-B-mediated transcription in hepatocytes in vitro. J Diabetes Complications,2007,21:56-62. [12] 侍洪斌,顾叶青,孟革,等. 果糖与非酒精性脂肪肝的关联性研究. 医学综述,2017,23:1685-1689. [13] Jois T,Chen W,Howard V,et al. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice. Mol Metab,2017,6:1381-1394. [14] Dentin R,Pegorier JP,Benhamed F,et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem,2004,279:20314-20326. [15] Zhang D,Tong X,Vandommelen K,et al. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. J Clin Invest,2017,127:2855-2867. [16] Shimano H,Sato R. SREBP-regulated lipid metabolism:convergent physiology-divergent pathophysiology. Nat Rev Endocrinol,2017,13:710-730. [17] Abdul-Wahed A,Guilmeau S,Postic C. Sweet sixteenth for ChREBP:established roles and future goals. Cell Metab,2017,26:324-341. |